Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT
· Real-Time Price · USD
26.03
0.39 (1.52%)
At close: May 28, 2025, 3:59 PM
26.26
0.88%
After-hours: May 28, 2025, 07:52 PM EDT
1.52% (1D)
Bid | 25.96 |
Market Cap | 19.2B |
Revenue (ttm) | n/a |
Net Income (ttm) | -240.75M |
EPS (ttm) | -0.34 |
PE Ratio (ttm) | -76.56 |
Forward PE | -57.44 |
Analyst | Buy |
Ask | 26.26 |
Volume | 1,719,877 |
Avg. Volume (20D) | 4,001,813 |
Open | 25.66 |
Previous Close | 25.64 |
Day's Range | 25.07 - 26.35 |
52-Week Range | 2.30 - 36.91 |
Beta | -0.95 |
About SMMT
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol SMMT
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for SMMT stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts1 month ago
-36.05%
Summit Therapeutics shares are trading lower. The ...
Unlock content with
Pro Subscription
1 month ago
+21.5%
Summit Therapeutics shares are trading higher after the company provided updates on its Phase 3 trial of Ivonescimab and announced it met its primary endpoint.